Clinical efficacy of bisoprolol and carvedilol in treatment of chronic heart failure

Objective To observe the efficacy and safety of bisoprolol in treatment of chronic heart failure(CHF).Method 125 patients with CHF(NYHA grade Ⅱ to Ⅳ,LVEF≤40%) were randomized into 2 groups: bisoprolol group and carvedilol group.The whole study lasted 30 weeks.Patients' heart function was evaluated during each follow-up examination and adverse events were recorded.Results The LVEF was improved significantly after treatment(increasing by 11% in bisoprolol group and 12% in carvedilol group,P0.01).The symptoms in both groups were improved,the numbers of cases of NYHA grade Ⅲ were reduced to 5(8.1%) in bisoprolol group and to 6(9.5%) in carvedilol group(P0.01).There was no significant difference in incidence of adverse events between bisoprolol group(32.3%)and carvedilol group(34.9%).Conclusion Bisoprolol is as safe and effective as carvedilol for treatment of chronic heart failure and has same long-term therapeutic efficacy.